Literature DB >> 19460634

A quantitative assessment of gene expression (QAGE) reveals differential overexpression of DOPEY2, a candidate gene for mental retardation, in Down syndrome brain regions.

Mohammed Rachidi1, Anne-Lize Delezoide, Jean-Maurice Delabar, Carmela Lopes.   

Abstract

The brain alterations and mental retardation in Down syndrome are associated with overdosage of chromosome 21 genes. To shed light on the understanding of the molecular effect of this genetic overdosage, gene expression studies have crucial importance to quantify expression variations in Down syndrome tissues compared to normal ones. Herein, an in situ Quantitative Assessment of Gene Expression (QAGE) was used to quantify and statistically analyze, for the first time, DOPEY2 expression variations in different regions of the Down syndrome human fetal brains and to compare them to corresponding normal brains. DOPEY2, which is localized in the Down Syndrome Critical Region (DSCR) and is a candidate gene for neurological alterations in Down syndrome, showed a delimited regional and cellular expression pattern in the cortex, hippocampus and cerebellum, characterized by different transcriptional intensities in both normal and trisomic brains. DOPEY2 is overexpressed more than 50% (1.79-, 1.97- and 2.12-folds in the cortex, cerebellum and hippocampus, respectively), and showed statistically significant differences in the overexpression ratios in the three brain regions expressing DOPEY2. The demonstration of differential DOPEY2 expression and overexpression in human fetal brains suggests that this gene is submitted to a complex transcriptional control and could depend from other human chromosome 21 genes. Moreover, DOPEY2 overexpression in the brain regions, that are altered in Down syndrome patients and involved in learning and memory processes, is in agreement to the hypothesis that this gene plays a potential role in functional brain alterations and in the pathogenesis of mental retardation in Down syndrome. This new in situ QAGE approach allowed quantitative measurements of transcriptional changes and statistical evaluations of the expression and overexpression patterns of DOPEY2 at specific regions of the brain, which is a complementary approach to qRT-PCR and microarray for transcriptome study. Moreover, this approach could be a powerful tool to study the candidate chromosome 21 genes for Down syndrome and other pathologies caused by regionalized quantitative transcriptional alterations, for greater interpretation of functional processes driving gene expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460634     DOI: 10.1016/j.ijdevneu.2009.02.001

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  9 in total

1.  Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study.

Authors:  Shanker Swaminathan; Li Shen; Sungeun Kim; Mark Inlow; John D West; Kelley M Faber; Tatiana Foroud; Richard Mayeux; Andrew J Saykin
Journal:  Curr Alzheimer Res       Date:  2012-09       Impact factor: 3.498

Review 2.  Developmental Neuropathology and Neurodegeneration of Down Syndrome: Current Knowledge in Humans.

Authors:  Zinnat Hasina; Nicole Wang; Chi Chiu Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-23

3.  Generation of a panel of antibodies against proteins encoded on human chromosome 21.

Authors:  Frances K Wiseman; Olivia Sheppard; Jacqueline M Linehan; Sebastian Brandner; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Negat Results Biomed       Date:  2010-08-20

4.  Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Dimitra Karampatsi; Nikolaos Papagiannakis; Matina Maniati; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Mov Disord       Date:  2021-01-12       Impact factor: 10.338

5.  A mutation in DOP1B identified as a probable cause for autosomal recessive Peters anomaly in a consanguineous family.

Authors:  Ensieh Darbari; Davood Zare-Abdollahi; Afagh Alavi; Mozhgan Rezaei Kanavi; Sepehr Feizi; Seyed Bagher Hosseini; Alireza Baradaran-Rafii; Hamid Ahmadieh; Shohreh Issazadeh-Navikas; Elahe Elahi
Journal:  Mol Vis       Date:  2020-11-25       Impact factor: 2.367

6.  Identification of contributing genes of Huntington's disease by machine learning.

Authors:  Jack Cheng; Hsin-Ping Liu; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  BMC Med Genomics       Date:  2020-11-23       Impact factor: 3.063

7.  Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.

Authors:  Shanker Swaminathan; Matthew J Huentelman; Jason J Corneveaux; Amanda J Myers; Kelley M Faber; Tatiana Foroud; Richard Mayeux; Li Shen; Sungeun Kim; Mari Turk; John Hardy; Eric M Reiman; Andrew J Saykin
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

8.  Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks.

Authors:  King-Hwa Ling; Chelsee A Hewitt; Kai-Leng Tan; Pike-See Cheah; Sharmili Vidyadaran; Mei-I Lai; Han-Chung Lee; Ken Simpson; Lavinia Hyde; Melanie A Pritchard; Gordon K Smyth; Tim Thomas; Hamish S Scott
Journal:  BMC Genomics       Date:  2014-07-22       Impact factor: 3.969

9.  Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.

Authors:  Aarti Ruparelia; Frances Wiseman; Olivia Sheppard; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Biomed Res       Date:  2010-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.